ES2611483T3 - Agente terapéutico para enfermedad inflamatoria intestinal - Google Patents

Agente terapéutico para enfermedad inflamatoria intestinal Download PDF

Info

Publication number
ES2611483T3
ES2611483T3 ES09770108.0T ES09770108T ES2611483T3 ES 2611483 T3 ES2611483 T3 ES 2611483T3 ES 09770108 T ES09770108 T ES 09770108T ES 2611483 T3 ES2611483 T3 ES 2611483T3
Authority
ES
Spain
Prior art keywords
inflammatory bowel
therapeutic agent
bowel disease
diphenylpyrazin
butyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09770108.0T
Other languages
English (en)
Inventor
Takashi Kyoi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of ES2611483T3 publication Critical patent/ES2611483T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ácido 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}acético o 2-{4-[N-(5,6-difenilpirazin-2-il)-Nisopropylamino] butiloxi}-N-(metilsulfonil)acetamida, o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento de enfermedades inflamatorias intestinales

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES09770108.0T 2008-06-23 2009-06-22 Agente terapéutico para enfermedad inflamatoria intestinal Active ES2611483T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008162640 2008-06-23
JP2008162640 2008-06-23
PCT/JP2009/061287 WO2009157398A1 (ja) 2008-06-23 2009-06-22 炎症性腸疾患治療剤

Publications (1)

Publication Number Publication Date
ES2611483T3 true ES2611483T3 (es) 2017-05-09

Family

ID=41444464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09770108.0T Active ES2611483T3 (es) 2008-06-23 2009-06-22 Agente terapéutico para enfermedad inflamatoria intestinal

Country Status (16)

Country Link
US (1) US8394793B2 (es)
EP (1) EP2289518B1 (es)
JP (1) JP5527206B2 (es)
KR (1) KR101639821B1 (es)
CN (1) CN102065864B (es)
CA (1) CA2728161C (es)
CY (1) CY1118390T1 (es)
DK (1) DK2289518T3 (es)
ES (1) ES2611483T3 (es)
HR (1) HRP20170030T1 (es)
HU (1) HUE032108T2 (es)
LT (1) LT2289518T (es)
PL (1) PL2289518T3 (es)
PT (1) PT2289518T (es)
SI (1) SI2289518T1 (es)
WO (1) WO2009157398A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102705198B1 (ko) 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (ja) * 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
CN104586853A (zh) * 2014-12-31 2015-05-06 武汉联程生物科技有限公司 一种用于治疗外伤性颅脑创伤的药物组合物及其制备方法
AU2016366073B2 (en) * 2015-12-02 2021-08-26 Nippon Shinyaku Co., Ltd. Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
CN109563055B (zh) * 2016-07-29 2021-12-24 成都苑东生物制药股份有限公司 氨基吡嗪类化合物或盐、异构体、其制备方法及用途
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
TWI801421B (zh) 2017-09-28 2023-05-11 日商日本新藥股份有限公司 結晶
BR112020008940A2 (pt) 2017-11-16 2020-10-20 Nippon Shinyaku Co., Ltd. preparação de liberação controlada
JP2021512902A (ja) 2018-02-07 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド プロスタサイクリン受容体アゴニスト
CA3154802A1 (en) 2019-10-23 2021-04-29 Marc Patrik SCHRADER Pharmaceutical composition comprising selexipag
WO2021152060A1 (en) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO440696A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. New use
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US7326716B2 (en) * 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
DK2246336T3 (da) * 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor

Also Published As

Publication number Publication date
LT2289518T (lt) 2017-01-10
CA2728161C (en) 2017-06-06
HUE032108T2 (en) 2017-08-28
CY1118390T1 (el) 2017-06-28
CA2728161A1 (en) 2009-12-30
JPWO2009157398A1 (ja) 2011-12-15
EP2289518A4 (en) 2012-04-11
EP2289518B1 (en) 2016-11-02
PT2289518T (pt) 2016-11-18
HRP20170030T1 (hr) 2017-03-24
JP5527206B2 (ja) 2014-06-18
CN102065864B (zh) 2012-11-21
US8394793B2 (en) 2013-03-12
KR20110036537A (ko) 2011-04-07
DK2289518T3 (en) 2017-01-16
CN102065864A (zh) 2011-05-18
US20110118254A1 (en) 2011-05-19
PL2289518T3 (pl) 2017-03-31
WO2009157398A1 (ja) 2009-12-30
SI2289518T1 (sl) 2017-02-28
KR101639821B1 (ko) 2016-07-14
EP2289518A1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
ES2611483T3 (es) Agente terapéutico para enfermedad inflamatoria intestinal
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
ES2525932T3 (es) Derivados de dihidrotetrabenazina radiomarcados y su uso como agentes de imagenología
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
ES2524556T3 (es) Composiciones farmacéuticas
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CL2007003192A1 (es) Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CU23497A3 (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
CL2011000663A1 (es) Compuestos derivados de n-heterociclil-2-sulfonil acetamida, moduladores del receptor cb2, utiles para el tratamiento del dolor, enfermedad pulmonar, reumatica, autoinmune, entre otras.
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
ES2531516T3 (es) Uso de escina
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis